Pyridoxalated haemoglobin polyoxyethylene

Drug Profile

Pyridoxalated haemoglobin polyoxyethylene

Alternative Names: Hemoximer; PHP; PHP-CT; PHP-HT; PHP-OC; Pyridoxalated haemoglobin polyethylene; VTR-PHP

Latest Information Update: 16 Oct 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ajinomoto
  • Developer Curacyte Inc
  • Class Haemoglobins; Polyethylene glycols
  • Mechanism of Action Nitric oxide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cardiogenic shock

Highest Development Phases

  • Discontinued Rheumatoid arthritis; Septic shock; Shock

Most Recent Events

  • 26 Aug 2011 Discontinued - Phase-II for Shock in USA (IV)
  • 26 Aug 2011 Discontinued - Phase-III for Septic shock in European Union (IV)
  • 03 Feb 2011 Pyridoxalated haemoglobin polyoxyethylene is still in phase III trials for Septic shock in the European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top